Literature DB >> 24956976

Depressive symptoms in first-episode psychosis: a 10-year follow-up study.

Nasrettin Sönmez1,2, Jan Ivar Røssberg1,2, Julie Evensen1,2, Helene Eidsmo Barder1,3, Ulrik Haahr4, Wenche Ten Velden Hegelstad5, Inge Joa5,6, Jan Olav Johannessen5,6, Hans Langeveld5, Tor Ketil Larsen5,7, Ingrid Melle1,2, Stein Opjordsmoen1,2, Bjørn Rishovd Rund3,8, Erik Simonsen9, Per Vaglum10, Thomas McGlashan11, Svein Friis1,2.   

Abstract

AIMS: The present study examined if any patient characteristics at baseline predicted depressive symptoms at 10 years and whether patients prone to depressive symptoms in the first year of treatment had a different prognosis in the following years.
METHOD: A total of 299 first-episode psychosis (FEP) patients with schizophrenia spectrum disorders were assessed for depressive symptoms with PANSS depression item (g6) at baseline, and 1, 2, 5 and 10 years of follow up. At 10 years, depressive symptoms were also assessed with Calgary Depression Scale for Schizophrenia (CDSS). A PANSS g6 ≥ 4 and CDSS score ≥ 6 were used as a cut-off score for depression.
RESULTS: A total of 122 (41%) patients were scored as depressed at baseline, 75 (28%) at 1 year, 50 (20%) at 2 years, 33 (16%) at 5 years, and 35 (19%) at 10 years of follow up. Poor childhood social functioning and alcohol use at baseline predicted depression at 10 years of follow up. Thirty-eight patients were depressed at both baseline and 1 year follow up. This group had poorer symptomatic and functional outcome in the follow-up period compared to a group of patients with no depression in the first year of treatment.
CONCLUSION: Depressive symptoms are frequent among FEP patients at baseline but decrease after treatment because their general symptoms have been initiated. Patients with poor social functioning in childhood and alcohol use at baseline are more prone to have depressive symptoms at 10 years of follow up. Patients struggling with depressive symptoms in the first year of treatment should be identified as having poorer long-term prognosis.
© 2014 Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  depressive symptom; longitudinal study; psychosis

Mesh:

Year:  2014        PMID: 24956976     DOI: 10.1111/eip.12163

Source DB:  PubMed          Journal:  Early Interv Psychiatry        ISSN: 1751-7885            Impact factor:   2.732


  5 in total

1.  The relationship between antidepressant treatment and inflammatory markers in early psychosis: preliminary results.

Authors:  Alexander Stojanovic-Pérez; Lourdes Martorell; Itziar Montalvo; Laura Ortega; Montse Solé; Irene Moreno; Elisabet Vilella; Javier Labad
Journal:  Psychopharmacology (Berl)       Date:  2016-08-29       Impact factor: 4.530

2.  A Retrospective Study of the Clinical Characteristics Associated with Alcohol and Cannabis use in Early Phase Psychosis.

Authors:  Jacob Cookey; Jacob McGavin; Candice E Crocker; Kara Matheson; Sherry H Stewart; Philip G Tibbo
Journal:  Can J Psychiatry       Date:  2020-02-04       Impact factor: 4.356

3.  Depression, Cytokine, and Cytokine by Treatment Interactions Modulate Gene Expression in Antipsychotic Naïve First Episode Psychosis.

Authors:  Cristiano Noto; Vanessa Kiyomi Ota; Marcos Leite Santoro; Eduardo Sauerbronn Gouvea; Patricia Natalia Silva; Leticia Maria Spindola; Quirino Cordeiro; Rodrigo Affonseca Bressan; Ary Gadelha; Elisa Brietzke; Sintia Iole Belangero; Michael Maes
Journal:  Mol Neurobiol       Date:  2015-10-22       Impact factor: 5.590

4.  Suicidal behaviour after first-episode psychosis: results from a 1-year longitudinal study in Portugal.

Authors:  Ricardo Coentre; Alexandra Fonseca; Tiago Mendes; Ana Rebelo; Elisabete Fernandes; Pedro Levy; Carlos Góis; Maria Luísa Figueira
Journal:  Ann Gen Psychiatry       Date:  2021-07-06       Impact factor: 3.455

5.  Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia.

Authors:  L Hargarter; P Bergmans; P Cherubin; S Keim; A Conca; A Serrano-Blanco; I Bitter; N Bilanakis; A Schreiner
Journal:  Expert Opin Pharmacother       Date:  2016-05-09       Impact factor: 3.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.